Trial Profile

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE TITRATION, MULTI-CENTER STUDY to EVALUATE the SAFETY and EFFICACY of SUBCUTANEOUS MANP WHEN ADMINISTERED ONCE DAILY for 42 DAYS in PARTICIPANTS with DIFFICULT to CONTROL HYPERTENSION/RESISTANT HYPERTENSION

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 04 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Mar 2025 According to an E-Star Biotech media release, Results from this study presented at at the 2025 Annual Meeting of the American College of Cardiology.
05 Feb 2025 According to an E-Star Biotech media release, company announced that it has dosed its first patient.
03 Feb 2025 Planned number of patients changed from 132 to 120.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com